F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and Tc-MDP bone scintigraphy, using an adaptive trial design

retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013; 20: 478–483. 16. Bjarnason GA, Khalil B, Hudson JM et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 2014; 32: 480–487. 17. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794–5799. 18. Bracarda S, Sisani M, Marrocolo F et al. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol 2014; 89: 386–393. 19. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011; 16 (Suppl 2): 32–44. 20. Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol 2013; 24: 2935–2942. 21. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009; 122: 114–120. 22. Todo Y, Sakuragi N. Randomized controlled trial versus comparative cohort study in verifying the therapeutic role of lymphadenectomy in endometrial cancer. Int J Clin Oncol 2013; 18: 200–206. appendix